N.A.C.O.I.-N.I.o MS, India HIVE. 2017: Technical Report. New Delhi: NACO, Ministry of Health and Family Welfare, Government of India. 2018.

Maartens G, Celum C, Lewin SR. HIV infection: epidemiology, pathogenesis, treatment, and prevention. Lancet. 2014;384(9939):258–71.

Article  PubMed  Google Scholar 

Smith RL, de Boer R, Brul S, Budovskaya Y, van Spek H. Premature and accelerated aging: HIV or HAART? Front Genet. 2012;3:328.

PubMed  Google Scholar 

Rajasuriar R, Chong ML, Ahmad Bashah NS, Abdul Aziz SA, McStea M, Lee ECY, et al. Major health impact of accelerated aging in young HIV-infected individuals on antiretroviral therapy. AIDS. 2017;31(10):1393–403.

Article  CAS  PubMed  Google Scholar 

Appay V, Almeida JR, Sauce D, Autran B, Papagno L. Accelerated immune senescence and HIV-1 infection. Exp Gerontol. 2007;42(5):432–7.

Article  CAS  PubMed  Google Scholar 

Ianas V, Berg E, Mohler MJ, Wendel C, Klotz SA. Antiretroviral therapy protects against frailty in HIV-1 infection. J Int Assoc Provid AIDS Care. 2013;12(1):62–6.

Article  PubMed  Google Scholar 

Leeansyah E, Cameron PU, Solomon A, Tennakoon S, Velayudham P, Gouillou M, et al. Inhibition of telomerase activity by human immunodeficiency virus (HIV) nucleos(t)ide reverse transcriptase inhibitors: a potential factor contributing to HIV-associated accelerated aging. J Infect Dis. 2013;207(7):1157–65.

Article  CAS  PubMed  Google Scholar 

Auclair M, Guenantin AC, Fellahi S, Garcia M, Capeau J. HIV antiretroviral drugs, dolutegravir, maraviroc and ritonavir-boosted atazanavir use different pathways to affect inflammation, senescence and insulin sensitivity in human coronary endothelial cells. PLoS ONE. 2020;15(1):e0226924.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Quercia R, Roberts J, Martin-Carpenter L, Zala C. Comparative changes of lipid levels in treatment-naive, HIV-1-infected adults treated with dolutegravir vs. efavirenz, raltegravir, and ritonavir-boosted darunavir-based regimens over 48 weeks. Clin Drug Investig. 2015;35(3):211–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lombardi F, Belmonti S, Borghetti A, Ciccullo A, Baldin G, Cauda R, et al. Reduced soluble CD14 levels after switching from a dual regimen with lamivudine plus boosted protease inhibitors to lamivudine plus dolutegravir in virologically suppressed HIV-infected patients. HIV Res Clin Pract. 2019;20(3):92–8.

Article  CAS  PubMed  Google Scholar 

Gonzalez-Cordon A, Assoumou L, Moyle G, Waters L, Johnson M, Domingo P, et al. Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIV. J Antimicrob Chemother. 2021;76(9):2380–93.

Article  CAS  PubMed  Google Scholar 

Madzime M, Theron AJ, Anderson R, Tintinger GR, Steel HC, Meyer PWA, et al. Dolutegravir potentiates platelet activation by a calcium-dependent, ionophore-like mechanism. J Immunotoxicol. 2022;19(1):1–8.

Article  PubMed  Google Scholar 

Babu H, Ambikan AT, Gabriel EE, Svensson Akusjarvi S, Palaniappan AN, Sundaraj V, et al. Systemic inflammation and the increased risk of Inflamm-Aging and Age-Associated diseases in people living with HIV on Long Term suppressive antiretroviral therapy. Front Immunol. 2019;10:1965.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tenorio AR, Zheng Y, Bosch RJ, Krishnan S, Rodriguez B, Hunt PW, et al. Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment. J Infect Dis. 2014;210(8):1248–59.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shete A, Wagh V, Sawant J, Shidhaye P, Sane S, Rao A et al. Antiretroviral Treatment-Induced Galectin-9 might Impact HIV Viremia in Addition to contributing to Inflammaging. Int J Mol Sci. 2023;24(15).

Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med. 2006;12(12):1365–71.

Article  CAS  PubMed  Google Scholar 

Jiang W, Lederman MM, Hunt P, Sieg SF, Haley K, Rodriguez B, et al. Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection. J Infect Dis. 2009;199(8):1177–85.

Article  CAS  PubMed  Google Scholar 

Kitchens RL, Thompson PA, Viriyakosol S, O’Keefe GE, Munford RS. Plasma CD14 decreases monocyte responses to LPS by transferring cell-bound LPS to plasma lipoproteins. J Clin Invest. 2001;108(3):485–93.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Appay V, Fastenackels S, Katlama C, Ait-Mohand H, Schneider L, Guihot A, et al. Old age and anti-cytomegalovirus immunity are associated with altered T-cell reconstitution in HIV-1-infected patients. AIDS. 2011;25(15):1813–22.

Article  CAS  PubMed  Google Scholar 

Fowler K, Mucha J, Neumann M, Lewandowski W, Kaczanowska M, Grys M, et al. A systematic literature review of the global seroprevalence of cytomegalovirus: possible implications for treatment, screening, and vaccine development. BMC Public Health. 2022;22(1):1659.

Article  PubMed  PubMed Central  Google Scholar 

Das A, Munian D, Maity C, Pandey S, Paul S, Bhattacharya P. Prevalence of Cytomegalovirus infections in Blood donors and the newborn versus utility of leukocyte-reduced blood transfusion in the premature Newborn: An Observation from Eastern India. J Clin Neonatology. 2023;12(2):65–71.

Article  Google Scholar 

Perello R, Vergara A, Monclus E, Jimenez S, Montero M, Saubi N, et al. Cytomegalovirus infection in HIV-infected patients in the era of combination antiretroviral therapy. BMC Infect Dis. 2019;19(1):1030.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shete A, Dhayarkar S, Dhamanage A, Kulkarni S, Ghate M, Sangle S, et al. Possible role of plasma Galectin-9 levels as a surrogate marker of viremia in HIV infected patients on antiretroviral therapy in resource-limited settings. AIDS Res Ther. 2020;17(1):43.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sanada F, Taniyama Y, Muratsu J, Otsu R, Shimizu H, Rakugi H, et al. Source of chronic inflammation in aging. Front Cardiovasc Med. 2018;5:12.

Article  PubMed  PubMed Central  Google Scholar 

Ram B, Thakur R. Epidemiology and economic Burden of Continuing Challenge of Infectious diseases in India: analysis of Socio-demographic differentials. Front Public Health. 2022;10:901276.

Article  PubMed  PubMed Central  Google Scholar 

Batista MA, Calvo-Fortes F, Silveira-Nunes G, Camatta GC, Speziali E, Turroni S, et al. Inflammaging in endemic areas for infectious diseases. Front Immunol. 2020;11:579972.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cobos Jimenez V, Wit FW, Joerink M, Maurer I, Harskamp AM, Schouten J, et al. T-Cell activation independently associates with Immune Senescence in HIV-Infected recipients of long-term antiretroviral treatment. J Infect Dis. 2016;214(2):216–25.

Article  PubMed  Google Scholar 

Wu F, Simonetti FR. Learning from Persistent Viremia: mechanisms and implications for Clinical Care and HIV-1 cure. Curr HIV/AIDS Rep. 2023;20(6):428–39.

Article  PubMed  PubMed Central  Google Scholar 

Shete A, Jayawant P, Thakar M, Kurle S, Singh DP, Paranjape RS. Differential modulation of phenotypic composition of HIV-infected and -uninfected PBMCs during cryopreservation. J Immunoass Immunochem. 2013;34(4):333–45.

Article  CAS  Google Scholar 

Imamichi H, Lempicki RA, Adelsberger JW, Hasley RB, Rosenberg A, Roby G, et al. The CD8 + HLA-DR + T cells expanded in HIV-1 infection are qualitatively identical to those from healthy controls. Eur J Immunol. 2012;42(10):2608–20.

Article  CAS  PubMed  Google Scholar 

Lukas Yani S, Keller M, Melzer FL, Weinberger B, Pangrazzi L, Sopper S, et al. CD8(+)HLADR(+) Regulatory T cells change with aging: they increase in number, but lose checkpoint inhibitory molecules and suppressive function. Front Immunol. 2018;9:1201.

Article  PubMed  PubMed Central